Protocol Ledger

NCT05781750 · Phase II · TERMINATED

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Interventional Phase II clinical trial protocol NCT05781750 sponsored by Kezar Life Sciences in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-03 Enrollment: 84 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05781750
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)84 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05781750
Protocol FieldVerified Registry Value
NCT IdentifierNCT05781750
Consolidated Lead SponsorKezar Life Sciences
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment84 participants (ACTUAL)
Registered Start Date2023-11-03
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05781750
Hospital Research SiteLocationSite Profile
Guangdong Provincial People's HospitalGuangzhou, ChinaOpen Hospital Dossier ->
ZhuJiang Hospital of Southern Medical UniversityGuangzhou, ChinaOpen Hospital Dossier ->
Peking University Shenzhen HospitalShenzhen, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI